“It was an emotional decision, we are working on it, it’s still in a very early stage,” Datta said.
Datta said the potential antiviral is in an early pre-clinical (in vitro) stage.
The hunt for safe and effective Covid antivirals that can be used against Covid is on. Currently Pfizer’s Paxlovid and MSD-Ridgeback Biotherapeutics’ are two available options. Antivirals unlike monoclonal antibodies are capable of destroying viruses irrespective of mutations.
Along with antiviral – Bugworks is focused on advancing its lead molecule BWC0977 which is currently in Phase 1 clinical trial in Australia and is targeted against antimicrobial resistance (AMR) Datta said he expects the Phase-1 trial to end by November 2022.
“In the ongoing Phase-1 it is getting tested on healthy volunteers, in phase-2 it will be tested on the patients with types of infections,” Datta said.